IP Library › Granted Patent US 12,358,868
Granted Patent B2
US 12,358,868 · App. 18/454,685 · Granted Jul 15, 2025

Chemical derivatives and methods for synthesizing and compounding chemical derivatives related to capsaicin palmitate and capsaicin prodrugs

Inventors: Richard Daniel Carliss (Roanoke, VA); Jianxing William Huang (Betlehem, PA)
Assignee: Chorda Pharma, Inc.
C07C271/40C07C233/22C07C271/06C07D295/205C07D295/215
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,358,868
App. No.
18/454,685
Granted
Jul 15, 2025
Kind
B2
Abstract

Capsaicin compositions and methods for enhancing hydrophobicity of a molecule useful for pharmaceutical applications, including: (1) a prodrug using a linker such as a carbamate between capsaicin with other structures in order to optimize kinetic control of capsaicin cleavage; (2) a prodrug using a linker such as an unsaturated carboxylic ester between capsaicin with other structures in order to optimize kinetic control of capsaicin cleavage; (3) esters of long-chain fatty acids and capsaicin where hydroxyl groups provide handles for attachment of additional capsaicin molecules; and (4) the use of carboxylic acid diesters to increase overall hydrophobicity of two or more covalently-linked capsaicin molecules. Formulations of palmitated esters of capsaicin are also described, which are designed to enhance hydrophobicity of a molecule useful for pharmaceutical applications, for example to provide compounded mixtures designed to optimize analgesic efficacy.

Claims (22)

1. A prodrug of formula (I), (II) or (III):

wherein:

Cpsn represents a capsaicinoid which is joined at a free phenolic hydroxyl group via an ester-containing linkage of formula (I), (II) or (III);

R in formula (I), (II) and (III) is a C 1-20 branched, cyclized, saturated or unsaturated hydrocarbon, a molecule with analgesic properties, or a molecule with pharmacological properties; and

the unsaturated hydrocarbon moiety in formula (I) is a non-cyclic moiety having two carbon atoms, or

the unsaturated hydrocarbon moiety in formula (I) is a benzene moiety that is optionally substituted with up to four substituents selected from the group consisting of a straight, branched or cyclic C 1-6 hydrocarbon, a halogen, a hydroxyl, an alkoxyl, a nitrogen-containing substituent, and any combination thereof, such that two adjacent substituents may be joined to form a fused heterocyclic ring;

the saturated hydrocarbon moiety in formula (II) is a branched or cyclic C1-C20 hydrocarbon moiety; and

n is 6 to 20.

2. The prodrug of claim 1 , which is a prodrug of formula (I).

3. The prodrug of claim 1 , which is a prodrug of formula (II).

4. The prodrug of claim 1 , which is a prodrug of formula (III).

5. The prodrug of claim 1 , wherein R is a C 1-20 branched, cyclized, saturated or unsaturated hydrocarbon.

6. The prodrug of claim 1 , wherein R is a molecule with analgesic properties, or a molecule with pharmacological properties.

7. The prodrug of claim 6 , wherein R is Cpsn.

8. The prodrug of claim 2 , wherein the unsaturated hydrocarbon moiety in formula (I) is the non-cyclic moiety having two carbon atoms.

9. The prodrug of claim 8 , wherein the unsaturated hydrocarbon moiety having two carbon atoms derives from an α,β-unsaturated di-carboxylic acid comprising carbon atoms.

10. The prodrug of claim 2 , wherein the unsaturated hydrocarbon moiety in formula (I) is the benzene moiety that is optionally substituted with up to four substituents selected from the group consisting of a straight, branched or cyclic C 1-6 hydrocarbon, a halogen, a hydroxyl, an alkoxyl, a nitrogen-containing substituent, and any combination thereof, wherein two adjacent substituents may be joined to form a fused heterocyclic ring.

11. The prodrug of claim 10 , wherein the benzene moiety is optionally substituted with up to four substituents selected from the group consisting of a cyclic C 3-6 hydrocarbon, a halogen, an alkoxy, and any combination thereof, wherein two adjacent alkoxy substituents may be joined to form a fused heterocyclic ring.

12. The prodrug of claim 11 , wherein the benzene moiety is a structure of formula:

13. The prodrug of claim 3 , wherein the saturated hydrocarbon moiety in formula (II) is a branched C 1 -C 20 hydrocarbon moiety.

14. The prodrug of claim 3 , wherein the saturated hydrocarbon moiety in formula (II) is a cyclic C 1 -C 20 hydrocarbon moiety.

15. A composition, comprising: the prodrug of claim 1 , and at least one of water, an oil, a surfactant, an emulsifier, a stabilizer, a chelator, a preservative, and a pH-adjusting agent.

Continuity (4)
Division 17673381 · Feb 16, 2022
Continuation PCTUS2020046861 · Aug 18, 2020
Provisional Application 62889002 · Aug 19, 2019
Related Publication 20230406816A1 · Dec 21, 2023
References Cited (12)
US 20040146590A1 · Iadarola et al. · 2004 [cited by applicant]
US 20100120912A1 · Singh et al. · 2010 [cited by applicant]
US 20160145225A1 · Husfeld · 2016 [cited by examiner]
US 20180016202A1 · Lombardi · 2018 [cited by examiner]
US 20190055272A1 · Husfeld et al. · 2019 [cited by applicant]
US 20220168259A1 · Carliss · 2022 [cited by examiner]
CN 101774938 · 2010 [cited by examiner]
CN 104447777 · 2015 [cited by examiner]
‘Hydrocarbons’ ( IUPAC Compendium of Chemical Terminology, 3rd ed. International Union of Pure and Applied Chemistry; 2006. Online version 3.0.1, 2019. https://doi.org/10.1351/goldbook.H02889 ) (Year: 2006). [cited by examiner]
Machine generated translation of CN104447777, obtained Nov. 2024 (Year: 2024). [cited by examiner]
Machine generated translation of CN 101774938, obtained Nov. 2024 (Year: 2024). [cited by examiner]
International Search Report and Written Opinion for Application No. PCT/US2020/046861, dated Dec. 18, 2020, 9 pages. [cited by applicant]